Yüklüyor......
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
OBJECTIVE: The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular (CV) mortality by 38% in patients with type 2 diabetes (T2D) and CV disease. Here we compare outcomes with empagliflozin in older patients in EMPA-RE...
Kaydedildi:
| Yayımlandı: | Age Ageing |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7963112/ https://ncbi.nlm.nih.gov/pubmed/31579904 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ageing/afz096 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|